DAYTON, N.J., Feb. 6 /PRNewswire/ -- Phytomedics Inc., a private life sciences company focused on the discovery and development of novel plant-derived healthcare products, is pleased to announce the signing of an agreement with Henkel KGaA, one of the world's largest chemical companies, to develop innovative and proprietary botanical ingredients for cosmetic applications.
"We are very pleased to be working with Henkel KGaA, a world leader in developing novel body care and cosmetic products," said Dr. Bertold Fridlender, CEO of Phytomedics Inc. "Henkel's expertise in these areas complements Phytomedics' unique and proprietary discovery and development technologies. This synergy presents an opportunity for the commercialization of a new generation of novel, safe and effective botanical cosmetic ingredients."
Phytomedics is a unique life sciences company merging plant biology, biotechnology and medicinal chemistry for the development of innovative healthcare products. Phytomedics conducts its R&D under the leadership of Professor Ilya Raskin, Ph.D., at the Biotech Center of Rutgers University, who is also a founder and Chairman of the Company. Phytomedics has a broad research and licensing agreement with Rutgers University that allows the Company to exclusively license its core technologies and products.
Phytomedics has developed a broad range of plant-based technologies targeted for the discovery and manufacturing of novel pharmaceuticals, nutritional and health care products. Phytomedics has several products in various stages of development, including products for viral, auto-immune, inflammatory and cardiovascular diseases, cancer, diabetes, erectile dysfunction and sleep improvement, some of which are in clinical trials.
SOURCE: Phytomedics Inc.